Hyung Heon Kim

Showing: 1 - 1 of 1 Articles

NeuroBo Pharmaceuticals Phase 2a Clinical Trial

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the …

vinay April 1, 2024April 1, 2024